#USA #New York #Everest Group #agentic AI #ACTO

ACTO's Recognition as a Luminary

In a significant achievement within the realm of artificial intelligence applied to life sciences, ACTO has been recognized as a Luminary in the Innovation Watch: Agentic AI in Life Sciences Commercial 2026 report by Everest Group. This prominent acknowledgment underscores ACTO's commitment to blending human intelligence with empathetic AI, revolutionizing the commercial landscape of life sciences.

The Highlight of Everest Group's Report

Everest Group's assessment evaluates 22 leading providers in the field of AI products and platforms, focusing on their market performance and ecosystem drivers. Within this framework, companies are categorized into Luminaries, Fast Followers, Influencers, or Seekers, with ACTO achieving the prestigious Luminary status—a testament to its exceptional market performance and robust ecosystem engagement.

The Innovation Watch report comes at a time when agentic AI is proving to be a transformative force for commercial operations in life sciences. It identifies various opportunities across sales, marketing, medical affairs, market access, and patient services, as organizations increasingly turn to agentic AI to enhance decision-making processes, automate workflows, coordinate actions among systems, and foster personalized interactions.

Rohit K, Practice Director at Everest Group, remarked on the shift from isolated AI applications to connected commercial platforms that integrate data, content, and workflows across various roles and systems. He noted, "The value of agentic AI is contingent upon its ability to coordinate activities between systems and functions while maintaining governance, traceability, and human accountability," showcasing ACTO's role-based approach to AI within the life sciences sector.

ACTO's Innovative Approach to AI

ACTO stands out in the crowded AI landscape due to its unique focus on role-based agentic AI solutions. By integrating domain-specific SuperAgents with multiplatform orchestration and governance tailored for life sciences, ACTO has established itself as a benchmark in the industry. Its expanding partner ecosystem and early client implementations further solidify ACTO’s position as a leader in the field.

The recognition by Everest Group is the culmination of a long-standing strategy centered on agentic AI investments beginning in 2022. The journey commenced with LAICA, an IA-powered conversational assistant for life sciences learning, which has now evolved into the ACTO SuperAgents, launched in 2026.

Parth Khanna, ACTO's co-founder and CEO, expressed his gratitude for being named a Luminary, stating, "This honor reflects our ongoing commitment to empower the workforce in life sciences, leveraging AI not as a replacement, but as a capacity enhancer for human agents. Our clients are experiencing substantial value through our role-specific SuperAgents, which understand their work environment and the highly regulated aspects of their roles."

The Impact of ACTO's SuperAgents

ACTO's platform is uniquely crafted for the life sciences sector, combining its AI-driven field excellence with role-based SuperAgents that interact with multiple systems to provide real-time, regulatory-compliant support. This allows professionals who engage directly with clients to spend less time managing systems and more on developing relationships with healthcare providers.

The recognition adds to ACTO’s previous accolades, including being listed among the Top 50 Pharmaceutical Technology Providers for 2026 by Everest Group, reinforcing the company’s continued dedication to AI-driven excellence and specialized solutions tailored for life sciences.

Looking to the Future

ACTO is poised for future advancements in the realm of agentic AI, anticipating that the evolution of AI in life sciences will focus on creating a connected and intelligent workforce where both human talent and AI collaborate for optimal outcomes. This vision aligns with ACTO’s mission to not only enhance productivity but to significantly improve patient interactions post-regulatory approval.

For more details about ACTO’s innovative solutions and to download a free copy of the complete report, visit acto.com/superagents.

About Everest Group

Everest Group is a globally recognized research firm that empowers business leaders with insights for informed decision-making. Their PEAK Matrix® assessments provide in-depth analysis for service providers, products, and solutions in various market segments, thereby aiding stakeholders in comparing offerings against competitors. More information is available at www.everestgrp.com.

About ACTO

ACTO, trusted by 14 of the top 50 pharmaceutical companies, is reshaping how therapies reach patients post-regulatory approval. By integrating human intelligence with empathetic AI through its field excellence platform and AI SuperAgents, ACTO accelerates product launches and enhances client engagement. Committed to the highest regulatory standards, ACTO is validated by FDA 21 CFR Part 11 and certified as SOC 2 Type II. Learn more at www.acto.com.